title: Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a).
abstract: The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 outpatients who had serum Lp(a) levels higher than 20 mg/dL. The mean ( +/- SE) levels of Lp(a) decreased from 33.6 +/- 2.3 mg/dL to 23.5 +/- 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apolipoprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).
authors.affiliation: Department of Medical Information and Medical Records, Nagoya University Hospital, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yamauchi
authors.forename: Y
authors.initials: Y
authors.lastname: Tanahashi
authors.forename: M
authors.initials: M
authors.lastname: Okada
authors.forename: J
authors.initials: J
authors.lastname: Tsuzuki
authors.forename: A
authors.initials: A
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Abe
authors.forename: H
authors.initials: H
authors.lastname: Inagaki
authors.forename: H
authors.initials: H
authors.lastname: Agetsuma
authors.forename: R
authors.initials: R
authors.lastname: Hattori
authors.forename: H
authors.initials: H
authors.lastname: Izawa
mesh_terms: D000368:Aged; D001053:Apolipoproteins / Q000097:blood; D002784:Cholesterol / Q000097:blood; D005260:Female; D005340:Fibrinogen / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D017270:Lipoprotein(a) / Q000097:blood* / Q000187:drug effects; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D009531:Niceritrol / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D017270:Lipoprotein(a); D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D005340:Fibrinogen; D002784:Cholesterol; D009531:Niceritrol